Abstract
ObjectiveMultiple long-term conditions (MLTCs) are prevalent in rheumatoid arthritis (RA) and associated with worse outcomes and greater economic burden. However, little is known about the impact of MLTCs on the cost-of-illness (COI) in early RA, including direct and indirect costs. The objective of this study was to quantify this impact on COI.MethodsThe Scottish Early Rheumatoid Arthritis study is a national cohort of adults with new-onset RA. Direct costs were estimated applying relevant unit costs to health resource utilisation; indirect costs were measured by productivity loss due to health conditions. Two-part models were used, adjusting for age, gender, baseline functional disability and health-related quality of life. The Charlson Comorbidity Index score was calculated using ICD-10 diagnoses. Individuals were defined as ‘RA alone’, ‘RA plus LTC’ and ‘RA plus MLTCs’ according to the number of coexisting LTCs.ResultsData were available for 818 participants. Average annualised direct costs incurred by people with early RA plus MLTCs (£4444; 95% CI £3100 to £6371) were twice as, and almost five times higher than, those with a single LTC (£2184; 95% CI £1596 to £2997) and those without LTC (£919; 95% CI £694 to £1218), respectively. Indirect costs incurred by RA plus MLTCs (£842; 95% CI £377to £1521) were 3.1 times higher than RA alone (£530; 95% CI £273to £854). The relative proportion of direct costs increased with LTC category, ranging from 77.2% to 84.1%. In addition to increased costs with LTCs, costs also increased with age and were higher for men regardless of LTC category.ConclusionsMLTCs impact on COI early in the course of RA. The presence of LTCs is associated with significant increases in both direct and indirect costs among people with early RA.
Subject
Immunology,Immunology and Allergy,Rheumatology
Reference45 articles.
1. The pre-therapeutic classification of co-morbidity in chronic disease
2. Comorbidity or multimorbidity
3. MacMahon S et al . Multimorbidity: a priority for global health research. 127. London, UK: The Academy of Medical Sciences, 2018.
4. Whitty CJM , MacEwen C , Goddard A , et al . Rising to the challenge of multimorbidity. BMJ 2020:l6964.doi:10.1136/bmj.l6964
5. NICE . Multimorbidity: clinical assessment and management, 2016. Nice guideline. Available: https://www.nice.org.uk/guidance/ng56/resources/multimorbidity-clinical-assessment-and-management-1837516654789
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献